

DETAILED PROGRAM AGENDA

MONDAY, APRIL 23, 2018

7:00 AM-5:00 PM	Registration	Regency Ballroom Foyer
7:00 AM-12:00 PM	Poster Set-Up	Regency Ballroom Foyer
7:00-8:30 AM	Continental Breakfast	Regency Ballroom Foyer
8:30-10:00 AM	<p>Welcome</p> <p>William Schaffner, MD Medical Director National Foundation for Infectious Diseases (NFID)</p> <p>1000 - Opening Keynote Presentation Moderator: William Schaffner, MD</p> <p>The Power of Partnerships: Vaccinology as a Team Sport Bruce G. Gellin, MD, MPH President, Global Immunization, Sabin Vaccine Institute</p>	Regency Ballroom
10:00-11:00 AM	<p>1100 - Recent Progress & Developments in Preventing Emerging Infectious Diseases Moderator: Kayvon Modjarrad, MD, PhD Walter Reed Army Institute of Research</p> <p>Alan D.T. Barrett, PhD Director, Sealy Institute for Vaccine Sciences University of Texas Medical Branch</p> <p>Nelson L. Michael, MD, PhD Director, Walter Reed Army Institute of Research</p>	Cabinet/Judiciary Suite
10:00-11:00 AM	<p>1101 - Using Vaccines to Combat Antimicrobial Resistance Moderator: Kathleen M. Neuzil, MD, MPH University of Maryland School of Medicine</p> <p>10:00-10:15 AM Vaccines as a Tool to Combat Antimicrobial Resistance Martin H. Friede, PhD Coordinator, Initiative for Vaccine Research World Health Organization</p> <p>10:15-10:30 AM Case Study: Typhoid Vaccines in Low-Resource Settings Kathleen M. Neuzil, MD, MPH</p> <p>10:30-10:45 AM An Industry Perspective on the Complexities of Developing AMR Vaccines Phyllis A. Arthur, MBA Vice President, Infectious Diseases and Diagnostics Policy Biotechnology Innovation Organization (BIO)</p>	Regency Ballroom
11:00-11:30 AM	Coffee Break	Regency Ballroom Foyer

DETAILED PROGRAM AGENDA

ORAL ABSTRACT PRESENTATIONS

11:30 AM-1:00 PM	<p>1200 - Vaccines to Combat Gastrointestinal Illness Moderator: Nicola P. Klein, MD, PhD Kaiser Permanente Vaccine Study Center Cabinet/Judiciary Suite</p>	<p>1201 - New Developments in Influenza Vaccines Moderator: Daniel B. Jernigan, MD, MPH Centers for Disease Control and Prevention Regency Ballroom</p>
11:30-11:45 AM	<p>OA1-1 A Multivalent Norovirus Vaccine Induces Strong Immune Responses Against Homologous and Heterologous Strains in Experimental Animals Lauren A. Ford-Siltz, PhD Staff Fellow US Food and Drug Administration</p>	<p>OA2-1 A Plant-Made Virus-Like Particle (VLP) Vaccine Bearing The Hemagglutinin Protein of H1N1 A/California/07/2009 Protects against Frailty in An Aged Mouse Influenza Challenge Model Breanna Hodgins PhD Student, Research Institute - McGill University Health Centre</p>
11:45 AM-12 PM	<p>OA1-2 Lack of Interference of an IPV-IRV Combination Vaccine in Animal Models Baoming Jiang, DVM, PhD Team Lead, Centers for Disease Control and Prevention</p>	<p>OA2-2 Intrinsic Adjuvant Properties of Plant-Made Virus-Like Particle Vaccines for Influenza Hilary E. Hendin PhD Candidate, McGill University</p>
12:00-12:15 PM	<p>OA1-3 Sex-Based Differences in Immune Responses to Vaccination Inna G. Ovsyannikova, PhD Professor of Medicine, Mayo Clinic</p>	<p>OA2-3 Influenza Vaccination Based on Conserved Antigens: Impact of Immunization Route and Target Antigens on Reduction of Virus Transmission Suzanne L. Epstein, PhD Associate Director for Research US Food and Drug Administration</p>
12:15-12:30 PM	<p>OA1-4 Direct, Indirect, and Overall Impact of Infant Rotavirus Vaccination Across Age Groups in the United States: A Time-Series Analysis of National Claims Data from 2002-2015 Julia M. Baker, MPH PhD Candidate, Emory University</p>	<p>OA2-4 AS03 Adjuvant Promotes Antibody Diversity and Affinity Maturation Against H5N1 with Improved Cross-Clade H5N1 Neutralization, Higher Neuraminidase Inhibition, but Limited Cross-Subtype H1N1 Virus Neutralization Surender Khurana, PhD Scientist, US Food and Drug Administration</p>
12:30-12:45 PM	<p>OA1-5 Estimates of the Global Morbidity, Mortality, and Etiologies of Diarrhea: A Systematic Analysis for the Global Burden of Disease Study Ibrahm A. Khalil, MD, MPH Senior Associate, Institute For Health Metrics and Evaluation, University of Washington</p>	<p>OA2-5 Mucosal Immune Responses Following Oral Tablet Delivery in Humans of Vaccines to Prevent Influenza or Norovirus Infection Sean Tucker, PhD Chief Scientific Officer, Vaxart, Inc.</p>
12:45-1:00 PM	<p>OA1-6 The Global Burden of Rotavirus Mortality Informing Rotavirus Vaccines Development and Delivery Strategies I. A. Khalil, MD, MPH Senior Associate, Institute For Health Metrics and Evaluation, University of Washington</p>	<p>OA2-6 A Clinical Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Novel Avian Cell Line, in Healthy Adult Volunteers Pedro Folegatti, MD, DTM&H, MPH Clinical Research Fellow, University of Oxford</p>

DETAILED PROGRAM AGENDA

1:00-2:15 PM	Lunch (On Your Own): NFID Fundraising Event at Gusto Details on page 23	
1:30-2:15 PM	Poster Presentations Details on page 24	Regency Ballroom Foyer
2:15-3:30 PM	1300 - Communicating About Vaccines in a Post-Fact World Moderator: William Schaffner, MD	Cabinet/Judiciary Suite
2:15-2:35 PM	Developing a Vaccine Confidence Index Robert A. Bednarczyk, PhD Assistant Professor, Emory University	
2:35-2:55 PM	Geography of Vaccine Refusal in California and Impact of Legislation Paul L. Delamater, PhD Assistant Professor, Department of Geography University of North Carolina at Chapel Hill	
2:55-3:15 PM	Nudges to Increase Vaccine Compliance Alison M. Bутtenheim, PhD, MBA Associate Professor of Nursing and Health Policy University of Pennsylvania	
2:15-3:30 PM	1301 - The Science of Vaccine Adverse Events Moderator: Saad B. Omer, MBBS, MPH, PhD Emory University & Emory Vaccine Center	Regency Ballroom
2:15-2:35 PM	Approaches for Studying Maternal Vaccine Safety Elyse O. Kharbanda, MD, MPH Senior Research Investigator, HealthPartners Institute	
2:35-2:55 PM	Immunology of Vaccine Adverse Events Cosby A. Stone, Jr., MD, MPH Division of Allergy & Immunology Vanderbilt University Medical Center	
2:55-3:15 PM	Emerging Issues in Clinical Vaccine Adverse Event Science Neal A. Halsey, MD Director, Institute for Vaccine Safety Johns Hopkins School of Public Health	
3:30-4:00 PM	Coffee Break & Poster Presentations	Regency Ballroom Foyer

DETAILED PROGRAM AGENDA

4:00-5:15 PM	<p>1400 - Mumps Control with Current Vaccines Moderator: Alison C. Mawle, PhD Centers for Disease Control and Prevention</p>	Cabinet/Judiciary Suite
4:00-4:30 PM	<p>Epidemiology of Mumps and the Role of Public Health Patricia Quinlisk, MD, MPH Medical Director/State Epidemiologist Iowa Department of Public Health</p>	
4:30-5:00 PM	<p>Mumps Vaccine Effectiveness and Waning Immunity Steven A. Rubin, PhD Chief, Laboratory of Method Development, Center for Biologics Evaluation and Research, US Food and Drug Administration</p>	
4:00-5:15 PM	<p>1401 - Designing and Evaluating CMV Vaccines Moderator: Cristina G. Cassetti, PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health</p>	Regency Ballroom
4:00-4:20 PM	<p>Overview and Evaluation of CMV Vaccines in Clinical Trials Stanley A. Plotkin, MD Emeritus Professor of Pediatrics University of Pennsylvania Principal, Vaxconsult</p>	
4:20-4:35 PM	<p>Regulatory Considerations for CMV Vaccine Licensure Jeffrey N. Roberts, MD Branch Chief, Clinical Review Branch 1 US Food and Drug Administration</p>	
4:35-4:50 PM	<p>The Extent of Protection of the Maternal-Placental-Fetal Unit Against CMV Infection and Disease Using Animal Models of Infection Mark R. Schleiss, MD Professor, Department of Pediatrics Director, Division of Pediatric Infectious Diseases and Immunology, University of Minnesota Medical School</p>	
4:50-5:05 PM	<p>Next Generation CMV Vaccines: Building on Lessons from the Past Sallie R. Permar, MD, PhD Professor, Pediatrics, Immunology, Molecular Genetics and Microbiology, Duke University School of Medicine</p>	
5:30-6:30 PM	Welcome Reception & Poster Presentations	Regency Ballroom Foyer

DETAILED PROGRAM AGENDA

TUESDAY, APRIL 24, 2018

7:00 AM-5:00 PM	Registration	Regency Ballroom Foyer
7:00-8:30 AM	Continental Breakfast & Poster Presentations	Regency Ballroom Foyer
7:30-8:30 AM	<p>Building Research Careers in Vaccinology Workshop Moderators: Kathleen M. Neuzil, MD, MPH H. Keipp B. Talbot, MD, MPH Vanderbilt University School of Medicine</p> <p>Gregory A. Poland, MD Professor of Medicine, Mayo Clinic and Foundation</p> <p>Octavio Ramilo, MD Chief, Division of Infectious Diseases Nationwide Children's Hospital</p> <p>Arthur L. Reingold, MD Professor and Division Head, Epidemiology University of California Berkeley, School of Public Health</p> <p>Raphael Simon, PhD Assistant Professor, University of Maryland</p> <p>Victoria A. Statler, MD, MS Assistant Professor, Pediatric Infectious Diseases University of Louisville</p>	Cabinet/Judiciary Suite
8:30-9:30 AM	<p>2000 - Mary Lou Clements-Mann Memorial Lecture in Vaccine Sciences Moderator: Walter A. Orenstein, MD, NFID President</p> <p>Strategies for Induction of Protective HIV Antibodies Barton F. Haynes, MD Frederic M. Hanes Professor of Medicine Director of the Human Vaccine Institute Professor of Global Health, Professor of Immunology Duke University School of Medicine</p>	Regency Ballroom
9:30-10:00 AM	Coffee Break & Poster Presentations	Regency Ballroom Foyer

DETAILED PROGRAM AGENDA

10:00-11:30 AM	<p>2100 - Biomarkers in the Development of Preventative Vaccines Moderator: Marion F. Gruber, PhD US Food and Drug Administration</p>	Old Georgetown/ Congressional Suite
10:00-10:20 AM	<p>Role of Antibody Affinity as Marker for Protection Against Pandemic Influenza Surender Khurana, PhD Scientist, US Food and Drug Administration</p>	
10:20-10:40 AM	<p>Functional Assays and Genetic Biomarkers to Improve Development of Vaccines Against Tuberculosis Sherry L. Kurtz, MS Research Biologist, US Food and Drug Administration</p>	
10:40-11:00 AM	<p>The Infant Immune System in Infection and Vaccination Octavio Ramilo, MD Chief, Division of Infectious Diseases Nationwide Children's Hospital</p>	
10:00-11:30 AM	<p>2101 - Epidemiology Mysteries in Vaccinology Moderator: Nicola P. Klein, MD, PhD</p>	Cabinet/Judiciary Suite
10:00-10:25 AM	<p>A New Conceptual Framework for Research on Vaccine Effectiveness: An Overview on Approaching VE Studies Nicola P. Klein, MD, PhD Director, Kaiser Permanente Vaccine Study Center</p>	
10:25-10:50 AM	<p>Approaches to Assessing the Effectiveness and Impact of HPV Vaccines Arthur L. Reingold, MD Professor and Division Head, Epidemiology University of California Berkeley, School of Public Health</p>	
10:50-11:15 AM	<p>Vaccine Effectiveness Studies Using the Test-Negative Design—Biases and Benefits Sheena G. Sullivan, PhD Senior Epidemiologist, World Health Organization</p>	
10:00-11:30 AM	<p>2102 - Ethical Considerations in Vaccine Trials Moderator: Bruce G. Gellin, MD, MPH</p>	Chesapeake Suite
10:00-10:20 AM	<p>Vaccine Trials in Low- and Middle-Income Countries: Regulatory Landscape and Ethical Challenges Carla Saenz, PhD Regional Bioethics Advisor, Knowledge Management, Bioethics and Research, Pan American Health Organization</p>	
10:20-10:40 AM	<p>Ethical Considerations in Vaccine Trial Design Rebecca J. Kahn Epidemiology Graduate Student Harvard T.H. Chan School of Public Health</p>	
10:40-11:00 AM	<p>Pregnant Women and the Vaccine R&D Agenda Carleigh B. Krubiner, PhD Research Scholar and Project Director Johns Hopkins Berman Institute of Bioethics</p>	

DETAILED PROGRAM AGENDA

11:45 AM-1:15 PM	<p>2200 - NFID Luncheon (details on page 9) Moderator: William Schaffner, MD</p> <p>Robert Austrian Memorial Lecture Carlos G. Grijalva, MD, MPH PLAN Course Director, Associate Professor of Health Policy Vanderbilt University School of Medicine</p> <p>Dr. Charles Meriéux Award Presentation for Achievement in Vaccinology and Immunology John F. Modlin, MD Deputy Director, Polio, Bill & Melinda Gates Foundation</p> <p>Maurice R. Hilleman Early-Stage Career Investigator Award Presentation</p>	Regency Ballroom
------------------	---	------------------

ORAL ABSTRACT PRESENTATIONS

1:30 PM-3:00 PM	<p>2300 - Vaccine Design, Monitoring, and Measurement Moderator: Saad B. Omer, MBBS, MPH, PhD Cabinet/Judiciary Suite</p>	<p>2301 - Novel Discoveries in Vaccine Development Moderator: Alison C. Mawle, PhD Old Georgetown/Congressional Suite</p>
1:30-1:45 PM	<p>OA3-1 Intranasal Inoculation of Nubian Breed Goats with Rift Valley Fever Virus Produces a Robust Infection Model</p> <p>Andrea L. Kroeker, PhD Research Scientist, Canadian Food Inspection Agency</p>	<p>OA4-1 Protective Antigenic Sites in Respiratory Syncytial Virus G Attachment Protein: Central Conserved Domain not Essential for Protection</p> <p>Jeehyun Lee, PhD Postdoctoral Fellow, US Food and Drug Administration</p>
1:45 PM-2:00 PM	<p>OA3-2 Structural Studies of Zika Virus Broadly Neutralizing Antibodies</p> <p>Rajeshwer S. Sankhala Postdoctoral Research Fellow, US Military HIV Research Program, Walter Reed Army Institute of Research</p>	<p>OA4-2 Safety of a Two-Dose Adult Hepatitis B Vaccine, HEPLISAV-B(TM), Using a Toll-like Receptor 9 Agonist Adjuvant</p> <p>Randall N. Hyer, MD, PhD, MPH Vice President, Clinical Development and Medical Affairs, Dynavax</p>
2:00-2:15 PM	<p>OA3-3 Phase 1 Study of a Pentavalent Meningococcal Conjugate Vaccine (ACYWX)</p> <p>Wilbur H. Chen, MD Associate Professor, University of Maryland School of Medicine</p>	<p>OA4-3 Can IgG Antibodies to Tetanus Toxoid Distinguish Fully Vaccinated Children from Under- and Unvaccinated Children? An Opportunity to Use Serology to Monitor Vaccination Programs</p> <p>Kyla Hayford, PhD, MA Assistant Scientist, Johns Hopkins Bloomberg School of Public Health</p>

DETAILED PROGRAM AGENDA

2:15-2:30 PM	<p>OA3-4 HIV-1 gp41 Residues Modulate Env Trimer CD4 Reactivity and gp120 Co-Evolution</p> <p>Paul W. Keller, PhD Staff Fellow, US Food and Drug Administration</p>	<p>OA4-4 Near Real-Time Surveillance to Assess the Post-Licensure Safety of the 9-Valent Human Papillomavirus Vaccine in the Vaccine Safety Datalink</p> <p>Kayla E. Hanson, MPH Epidemiologist, Marshfield Clinic Research Institute</p>
2:30-2:45 PM	<p>OA3-5 Development of Single Dose Vaccines for Ebola, Lassa Fever, and Zika Using a Novel MVA Vector Platform Technology</p> <p>Farshad Guirakhoo, PhD Chief Scientific Officer, Geovax</p>	<p>OA4-5 A Novel, More Efficient, and More Effective Approach to <i>Ex Vivo</i> Vaccination Utilizing Antigen-Pulsed Peripheral Blood Mononuclear Cells (PBMCs) Administered via the Intranasal Route</p> <p>David R. Nalin, MD Professor Emeritus, Albany Medical College</p>
2:45-3:00 PM	<p>OA3-6 Vaccination Patterns in Children after Autism Spectrum Disorder Diagnosis and in their Younger Siblings</p> <p>Oussen Zerbo, PhD Staff Scientist, Kaiser Permanente Northern California</p>	<p>OA4-6 Waning Immunity to MMR-II Vaccine?</p> <p>Richard B. Kennedy, PhD Associate Professor of Medicine Mayo Clinic</p>
3:00-3:30 PM	Coffee Break & Posters Presentations	
3:00-3:30 PM		Regency Ballroom Foyer
3:30-4:30 PM	<p>2400 - Communicating Science: Writing Effective Scientific Papers (Workshop)</p> <p>Jill E. Kolesar, PhD Associate Scientific Director Complete Healthcare Communications</p> <p>Gregory A. Poland, MD</p>	Cabinet/Judiciary Suite
3:30-4:30 PM	<p>2401 - Vaccine-Preventable Diseases in Humanitarian Crises Moderator: H. Keipp B. Talbot, MD, MPH</p>	Regency Ballroom
3:30-3:50 PM	<p>Vaccine Preventable Disease in Humanitarian Emergencies Among Refugee and Internally Displaced Populations Angela K. Shen, ScD, MPH Senior Health Science Policy Advisor US Department of Health and Human Services</p>	
3:50-4:10 PM	<p>Vaccine-Preventable Diseases in Relocated Populations Patricia A. Stinchfield, RN, MS, CPNP, CIC Nurse Practitioner, Pediatric Infectious Disease and Immunology Senior Director, Infection Control and The Children's Immunization Project Children's Minnesota</p>	

DETAILED PROGRAM AGENDA

WEDNESDAY, APRIL 25, 2018

7:00 AM-1:00 PM	Registration	Regency Ballroom Foyer
7:30-8:30 AM	Richard J. Duma, MD, PhD, Meet the Experts Breakfast Sessions Speaker and topic details on page 8	Old Georgetown/ Congressional Suite
8:30-10:00 AM	3000 - Novel Vaccine Technologies & Applications in Infectious Diseases Moderator: Cristina G. Cassetti, PhD	Cabinet/Judiciary Suite
8:30-8:50 AM	Rapid Development & Deployment of Synthetic DNA for ID David B. Weiner, PhD Executive Vice President and WW Smith Chair Cancer Research Wistar Institute	
8:50-9:10 AM	Zika Vaccination and Immunity Theodore C. Pierson, PhD Senior Investigator, National Institute of Allergy and Infectious Diseases National Institutes of Health	
9:10-9:30 AM	Role of Controlled Human Infection Models in Advancing Vaccine Development Karen L. Kotloff, MD Division Head, Ped-Infectious Diseases and Tropical Medicine University of Maryland School of Medicine	
8:30-10:00 AM	3001 - Universal Vaccine Development Moderator: Kayvon Modjarrad, MD, PhD	Regency Ballroom
8:30-8:50 AM	Considerations for a Universal Influenza Virus Vaccine Peter M. Palese, PhD Chair, Department of Microbiology Professor Department of Medicine Icahn School of Medicine at Mount Sinai	
8:50-9:10 AM	Structure-Based Approach to a Cross-Reactive Flavivirus Vaccine M. Gordon Joyce, PhD Chief, Structural Biology, Walter Reed Army Institute of Research	
9:10-9:30 AM	Anticipating a Vaccine for the Next Coronavirus Outbreak Kizzmekia S. Corbett, PhD Senior Research Fellow, National Institutes of Health Vaccine Research Center	
9:30-9:50 AM	A Magic Bullet for Viral Hemorrhagic Fevers? What Do Pan-Ebola Monoclonals Teach Us? M. Javad Aman, PhD Chief Scientific Officer, Integrated Biotherapeutics	
10:00-10:30 AM	Coffee Break	Regency Ballroom Foyer

DETAILED PROGRAM AGENDA

<p>10:30-11:30 AM</p> <p>10:30-10:45 AM</p> <p>10:45-11:00 AM</p> <p>11:00-11:15 AM</p>	<p>3100 - Designing Adjuvants to Address Durability of Protection (non-CME) Moderator: Daniel B. Jernigan, MD, MPH</p> <p>Ligands of Pathogen Sensor, Retinoic Acid-Inducible Gene-I (RIG-I) as Molecular Adjuvant Suryaprakash Sambhara, DVM, PhD Lead, Immunology Laboratory Team, Influenza Division Centers for Disease Control and Prevention</p> <p>Development of Oil-in-Water Emulsion Adjuvant Systems and Mechanism of Action Rino Rappuoli, PhD Chief Scientist & Head of External Research and Development GlaxoSmithKline Vaccines</p> <p>Molecular Adjuvants against Cancer and Asthma Steven G. Reed, PhD Chief Executive Officer, Infectious Disease Research Institute</p>	<p>Cabinet/Judiciary Suite</p>
<p>10:30-11:30 AM</p> <p>10:45-10:50 AM</p> <p>10:50-11:10 AM</p>	<p>3101 - Live Attenuated Influenza Vaccine (LAIV): What Have We Learned & Where Do We Go Next? Moderator: Kathleen M. Neuzil, MD, MPH</p> <p>Effectiveness of LAIV in US Children: Past Successes and New Challenges Kathryn M. Edwards, MD Sarah H. Sell and Cornelius Vanderbilt Chair in Pediatrics Director, Vanderbilt Vaccine Research Program Professor of Pediatrics, Vanderbilt University School of Medicine</p> <p>LAIV Effectiveness: The Global View Justin R. Ortiz, MD, MS Associate Professor of Medicine University of Maryland School of Medicine</p>	<p>Regency Ballroom</p>
<p>11:30 AM-1:00 PM</p>	<p>3200 - Closing Keynote Presentation Moderator: Walter A. Orenstein, MD</p> <p>A Vision for Accelerating Translational Development: Introducing the Gates Medical Research Institute Penny M. Heaton, MD Chief Executive Officer Bill & Melinda Gates Medical Research Institute</p>	<p>Regency Ballroom</p>